miR-449 can inhibit SIRT1-SREBP signaling by reducing the expression of SIRT1, SREBP1c, and its downstream genes FASN and HMGCR, thereby controlling adipogenesis and cholesterol production in hepatoma cells. The gene discussed is FASN; the disease is hepatocellular carcinoma.